Brief: Newron Pharmaceuticals says encouraging preliminary results of Phase IIA study with Evenamide

Newron Pharmaceuticals SpA

03/01/2017 16:31

Jan 3 (Reuters) - Newron Pharmaceuticals SPA  NWRN.S  -  
    * Newron Pharmaceuticals SPA - Newron announces encouraging 
preliminary results of its Phase IIA study with Evenamide in 
patients with schizophrenia 
    * Newron Pharmaceuticals SPA- Evenamide in range of 15-25 mg 
bid (30-50 mg/day) was well tolerated 
    * Newron Pharmaceuticals SPA - Study shows patients treated 
with Evenamide showed improvement on symptoms of schizophrenia 
assessed by PANSS 
    * Newron Pharmaceuticals SPA- Two patients in Evenamide 
group discontinued treatment due to AES: Seizure (n=1) and 
Atrial Fibrillation (n=1) 
    * Newron Pharmaceuticals SPA - Study found no evidence of 
worsening of extrapyramidal symptoms, abnormal ECG findings with 
Evenamide treatment, compared to placebo 
 
Source text for Eikon:  ID:nBw5RJDsda  
Further company coverage:  NWRN.S  
 
 ((Bangalore.newsroom@thomsonreuters.com;))